GlassScriptPhysician profile
Kodi M Bone
NPI 1184886012
$7,539.74
in general payments reported to CMS, 2019-2025
60 companies · $2,327 in 2025
The $2,327 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $611 · 2023: $2,346 · 2024: $2,106 · 2025: $2,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,590 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,589.55 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $474.29 | 2022-2025 | Kisqali |
| Merck Sharp & Dohme LLC | $462.74 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $442.96 | 2022-2025 | Polivy, Venclexta, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $440.88 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $402.03 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Incyte Corporation | $377.28 | 2023-2025 | Jakafi |
| Eisai INC. | $298.03 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $278.72 | 2022-2025 | |
| Pfizer INC. | $257.07 | 2023-2025 | |
| Daiichi Sankyo INC. | $253.33 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Abbvie INC. | $221.45 | 2023-2025 | |
| Janssen Biotech, INC. | $214.45 | 2023-2025 | Erleada, Tecvayli, Akeega |
| Seagen INC. | $209.05 | 2021-2023 | Adcetris, Tukysa |
| Lilly USA, LLC | $201.18 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $185.01 | 2023-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $168.14 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Karyopharm Therapeutics INC. | $166.67 | 2022-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $159.26 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $151.89 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $141.83 | 2022-2024 | Tazverik, Onivyde |
| Beigene USA, INC. | $119.96 | 2022-2025 | Brukinsa, Tevimbra |
| Amneal Pharmaceuticals LLC | $111.26 | 2023-2025 | Avastin, Alymsys |
| Adc Therapeutics America, INC. | $98.62 | 2022-2025 | |
| Gilead Sciences, INC. | $96.66 | 2022-2025 | Trodelvy |
| Legend Biotech USA INC. | $94.08 | 2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $89.21 | 2021-2022 | |
| Pharmaessentia USA Corporation | $80.47 | 2022-2024 | Besremi |
| Tersera Therapeutics LLC | $77.53 | 2022-2025 | Zoladex, Xermelo |
| Puma Biotechnology, INC. | $72.81 | 2024-2025 | |
| Emd Serono, INC. | $72.80 | 2023-2024 | Tepmetko, Bavencio |
| Amgen INC. | $69.33 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Beone Medicines USA, INC. | $67.21 | 2025 | Brukinsa |
| Astellas Pharma US INC | $66.50 | 2023-2024 | Xospata, Vyloy |
| Rigel Pharmaceuticals, INC. | $60.92 | 2023-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $58.43 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $56.52 | 2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $53.81 | 2025 | Qinlock |
| Genmab U.S., INC. | $52.82 | 2023-2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $47.74 | 2024-2025 | Clonoseq |
| Springworks Therapeutics, INC. | $46.22 | 2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $45.99 | 2023-2025 | Pyrukynd |
| Coherus Oncology, INC. | $43.08 | 2024 | |
| Syndax Pharmaceuticals, INC. | $41.68 | 2025 | |
| Kite Pharma, INC. | $40.20 | 2024-2025 | Yescarta |
| Acrotech Biopharma INC. | $35.48 | 2023-2024 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $31.72 | 2025 | |
| Stemline Therapeutics INC. | $31.16 | 2024 | Orserdu, Elzonris |
| Pharmacyclics LLC, An Abbvie Company | $30.07 | 2023 | Imbruvica, Epkinly |
| Geron Corporation | $27.60 | 2025 | Rytelo |
| Cti Biopharma Corp. | $26.90 | 2022 | |
| Progenics Pharmaceuticals, INC. | $25.35 | 2023 | Pylarify |
| Blueprint Medicines Corporation | $22.17 | 2023 | Ayvakit |
| Tempus Ai, INC | $21.85 | 2025 | Xt Cdx |
| G1 Therapeutics, INC. | $20.06 | 2023 | Cosela |
| Aadi Bioscience, INC. | $19.87 | 2023 | Fyarro |
| Myovant Sciences INC. | $19.04 | 2022 | |
| Exelixis INC. | $17.81 | 2023 | Cabometyx |
| Caris Mpi, INC. | $14.87 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $13.77 | 2025 | |
| Foundation Medicine, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kodi Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.